Volume 6.24 | Jul 3

Prostate Cell News 6.24 July 3, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
New Family of Small RNAs Boosts Cell Proliferation in Cancer
Researchers have discovered a new species of tranferRNAs -derived small RNAs that are produced only in hormonally-driven breast and prostate cancers, and which contribute to cell proliferation. [Press release from Thomas Jefferson University discussing online prepublication in Proceedings of the National Academy of Sciences] Press Release | Abstract | Full Article
Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs
PUBLICATIONS (Ranked by impact factor of the journal)

Heat-Shock Factor 2 Is a Suppressor of Prostate Cancer Invasion
The authors report that heat-shock factors (HSF)2 suppresses tumor invasion of prostate cancer. In three-dimensional organotypic cultures and the in vivo xenograft chorioallantoic membrane model, HSF2 knockdown perturbs organoid differentiation and promotes invasiveness. [Oncogene] Full Article

Redox-Sensitive PEG–Polypeptide Nanoporous Particles for Survivin Silencing in Prostate Cancer Cells
Researchers report the engineering of intracellular redox-responsive nanoporous poly(ethylene glycol) (PEG)-poly(l-lysine) particles. The obtained particles exhibited no toxicity while maintaining the capability to deliver a small interfering RNA sequence targeting the anti-apoptotic factor, survivin, in prostate cancer cells. [Biomacromolecules] Abstract | Graphical Abstract

Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies
ODM-201 reduced the growth of androgen receptor-overexpressing VCaP prostate cancer cells both in vitro and in a castration-resistant VCaP xenograft model. [Sci Rep] Full Article

mPGES-1 in Prostate Cancer Controls Stemness and Amplifies EGFR-Driven Oncogenicity
Scientists investigated whether expression of intrinsic microsomal PGE synthase-1 (mPGES-1) enhanced aggressiveness of prostate cancer cells and might be critical for epidermal growth factor receptor (EGFR)-mediated tumor progression. [Endocr-Relat Cancer] Abstract

Cold Atmospheric Plasma Treatment Induces Anti-Proliferative Effects in Prostate Cancer Cells by Redox and Apoptotic Signaling Pathways
Researchers investigated the impact of cold atmospheric plasma on cellular proliferation and consecutive molecular response mechanisms in established prostate cancer cell lines. [PLoS One] Full Article

Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer Cells
Researchers investigated the inhibitory effect of novel imidazopyridine derivatives HIMP, M-MeI, OMP, and EtOP on different human castration-resistant prostate cancer cells. [PLoS One] Full Article

Assessment of the Anticancer Mechanism of Ferulic Acid via Cell Cycle and Apoptotic Pathways in Human Prostate Cancer Cell Lines
The authors investigated the effects of ferulic acid, a phenolic compound, on cell cycle, apoptosis, invasion, and colony formation in PC-3 and LNCaP prostate cancer cells. [Tumor Biol] Abstract

Crude Extract of Euphorbia formosana Induces Apoptosis of DU145 Human Prostate Cancer Cells Acts through the Caspase-Dependent and Independent Signaling Pathway
Investigators determined effects of crude extract of Euphorbia formosana (CEEF) on cell cycle distribution and induction of apoptosis in DU145 human prostate cancer cells in vitro. CEEF-induced cell morphological changes, decreased the percentage of viable cells, and induced S phase arrest and apoptosis in DU145 cells. [Environ Toxicol] Abstract

Epigenetically Altered miR-193b Targets Cyclin D1 in Prostate Cancer
Investigators determined if microRNA (miR)-193b targets cyclin D1 in prostate cancer. In 22Rv1 prostate cancer cells with low endogenous miR-193b expression, the overexpression of miR-193b reduced CCND1 mRNA levels and cyclin D1 protein levels. [Cancer Med] Full Article

HOXA1 Enhances the Cell Proliferation, Invasion and Metastasis of Prostate Cancer Cells
Researchers found that HOXA1 was highly expressed in prostate cancer cells. They then repressed the expression of HOXA1 by short hairpin RNA to investigate the function of HOXA1 in prostate cancer cells. Their in vitro data showed that knockdown of HOXA1 attenuated the growth, invasion and migration of prostate cancer DU-145 and PC-3 cells. [Oncol Rep] Abstract


Randomized Phase II Trial of Docetaxel with or without PSA-TRICOM Vaccine in Patients with Castrate-Resistant Metastatic Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1809)
Researchers assessed the clinical efficacy of the Prostvac-VF® vaccine in patients with castration-resistant metastatic prostate cancer receiving subsequent docetaxel chemotherapy. [Hum Vaccin Immunother] Abstract

Development of a Standardized Set of Patient-Centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach
The authors sought to develop a standard set of outcomes relevant to men with advanced prostate cancer to follow during routine clinical care. [Eur Urol] Abstract

Learn More: Standardized Tools for Cancer Research
The Genomic Evolution of Human Prostate Cancer
The authors evaluate recurrent prostate-specific mutations prior to discussing the mutational events that are shared both in prostate cancer and across multiple cancer types. From these data, they construct a putative overview of the genomic evolution of human prostate cancer. [Br J Cancer] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Tokai Pharmaceuticals Announces Initiation of Phase III ARMOR3-SV Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer
Tokai Pharmaceuticals, Inc. announced the initiation of ARMOR3-SV, Tokai’s pivotal Phase III clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor that has been associated with non-responsiveness to commonly-used oral therapies for mCRPC. [Tokai Pharmaceuticals, Inc.] Press Release

Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases
Celgene Corporation and Juno Therapeutics, Inc. announced a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on chimeric antigen receptor technology and T cell receptor technologies. [Juno Therapeutics, Inc.] Press Release

Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria
Roswell Park Cancer Institute (RPCI) and Lakeshore Cancer Center (LCC) have announced an affiliation that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, who will also have access to both training at RPCI and continuing professional education seminars they can participate in remotely. [Roswell Park Cancer Institute] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
Watch the webinar.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Metabolism in Cancer and Stromal Cells
September 8-10, 2015
Leuven, Belgium

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Position – Functional Cancer Genomics (Institute of Oncology Research)

Assistant Professor- Urology (University of California, Los Angeles)

Postdoctoral Fellow- Oncology (Oregon Health & Science University)

Research Technician (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellows – Molecular Mechanisms of Prostate Cancer Progression and Therapeutic Resistance (Tulane University School of Medicine)

Postdoctoral Fellowship – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic Lerner Research Institute)

Research Scientists – Tissue Biorepository and Data Resource for Prostate Cancer (NYU Langone Medical Center)

Postdoctoral Positions – Cancer, Stem Cell, and Developmental Biology (Columbia University Medical Center)

Senior Postdoctoral Position – Prostate Cancer (Institut Paoli Calmettes)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us